Equities research analysts predict that OraSure Technologies, Inc. (NASDAQ:OSUR) will post $0.09 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for OraSure Technologies’ earnings. OraSure Technologies reported earnings of $0.11 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 18.2%. The business is scheduled to announce its next quarterly earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that OraSure Technologies will report full-year earnings of $0.49 per share for the current fiscal year, with EPS estimates ranging from $0.48 to $0.49. For the next financial year, analysts anticipate that the business will post earnings of $0.40 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. The business had revenue of $40.18 million during the quarter, compared to the consensus estimate of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.07 earnings per share.

OSUR has been the topic of several recent research reports. Jefferies Group LLC increased their price objective on shares of OraSure Technologies from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, May 4th. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Saturday, May 6th. Canaccord Genuity increased their price objective on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. Stephens reiterated an “overweight” rating and issued a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. Finally, BidaskClub cut shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $15.46.

In related news, EVP Anthony Zezzo II sold 72,916 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $21.26, for a total value of $1,550,194.16. Following the completion of the sale, the executive vice president now directly owns 218,326 shares of the company’s stock, valued at approximately $4,641,610.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronny B. Lancaster sold 89,684 shares of the stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $14.79, for a total transaction of $1,326,426.36. Following the completion of the sale, the director now directly owns 6,295 shares of the company’s stock, valued at $93,103.05. The disclosure for this sale can be found here. Insiders sold a total of 1,036,670 shares of company stock valued at $19,807,152 over the last three months. 7.80% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in OSUR. BlackRock Inc. raised its stake in OraSure Technologies by 127,593.4% in the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after buying an additional 7,737,261 shares in the last quarter. Daruma Capital Management LLC raised its stake in OraSure Technologies by 2,761.0% in the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after buying an additional 2,722,886 shares in the last quarter. Norges Bank purchased a new stake in OraSure Technologies during the fourth quarter valued at about $9,786,000. Vanguard Group Inc. raised its stake in OraSure Technologies by 30.3% in the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after buying an additional 1,037,439 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in OraSure Technologies by 22.3% in the first quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock valued at $66,357,000 after buying an additional 934,700 shares in the last quarter. 89.76% of the stock is owned by institutional investors.

OraSure Technologies (OSUR) traded up 0.80% during trading on Friday, hitting $20.13. 450,651 shares of the stock traded hands. The firm has a 50-day moving average price of $18.91 and a 200 day moving average price of $14.42. OraSure Technologies has a 52-week low of $6.84 and a 52-week high of $21.59. The company has a market cap of $1.20 billion, a P/E ratio of 37.21 and a beta of 1.57.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/18/brokerages-expect-orasure-technologies-inc-osur-to-post-0-09-earnings-per-share.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.